Book of Abstracts. Rare diseases need innovative therapies — innovative therapies need scientific discoveries
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00138322" target="_blank" >RIV/00216224:14110/24:00138322 - isvavai.cz</a>
Výsledek na webu
<a href="https://munispace.muni.cz/library/catalog/book/2392" target="_blank" >https://munispace.muni.cz/library/catalog/book/2392</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Book of Abstracts. Rare diseases need innovative therapies — innovative therapies need scientific discoveries
Popis výsledku v původním jazyce
The conference brings together leading experts from academia, clinical settings and research institutions from across Central Europe to jointly address shared challenges in the field of rare diseases and advanced therapies. Leading experts in advanced therapy medicinal products (ATMPs) from the European Union make significant contributions to research throughout the entire ATMP lifecycle. The contributions in this proceedings cover several phases, from initial discovery and development to clinical trials, manufacturing, regulation and post-market surveillance. Their research addresses key challenges in the field, such as improving the efficacy, safety and scalability of gene therapies, cell therapies and tissue engineered products.
Název v anglickém jazyce
Book of Abstracts. Rare diseases need innovative therapies — innovative therapies need scientific discoveries
Popis výsledku anglicky
The conference brings together leading experts from academia, clinical settings and research institutions from across Central Europe to jointly address shared challenges in the field of rare diseases and advanced therapies. Leading experts in advanced therapy medicinal products (ATMPs) from the European Union make significant contributions to research throughout the entire ATMP lifecycle. The contributions in this proceedings cover several phases, from initial discovery and development to clinical trials, manufacturing, regulation and post-market surveillance. Their research addresses key challenges in the field, such as improving the efficacy, safety and scalability of gene therapies, cell therapies and tissue engineered products.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30230 - Other clinical medicine subjects
Návaznosti výsledku
Projekt
<a href="/cs/project/LM2023049" target="_blank" >LM2023049: Český národní uzel Evropské sítě infrastruktur klinického výzkumu</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů